评估对于疾病易发生进展的冠心病患者抗高胆固醇血症治疗的疗效。44名家族性高胆固醇血症CHD患者开始了降脂饮食或普罗布考(1 g/day)或考来替泊(30 g/day)治疗。经过5个月的单药治疗，所有患者继续进行饮食或两种药物治疗。到目前为止，联合治疗已持续3.4-4.1年，并导致血清脂质水平从基线的以下变化：总胆固醇降低48.5%, 低密度脂蛋白降低53.3%，高密度脂蛋白降低30.0%，甘油三酯升高14.5%。尽管高密度脂蛋白胆固醇也有所降低，低密度脂蛋白胆固醇的降低明显改善了患者的临床状况。

    To evaluate the effect of hypercholesterolemic treatment on coronary artery disease in patients known to be          susceptible to disease progression, 44 patients with familial hypercholesterolemia and coronary artery disease were      started on a lipid-lowering diet and either probucol (1 g/day) or colestipol (30 g/day). After 5 months of monotherapy,  all patients went on a regimen of diet and 2-drug therapy. To date, combination therapy has continued for 3.4 to 4.1     years, and has resulted in the following changes from baseline in mean serum lipid levels: -48.5% in total cholesterol,  -53.3% in low density lipoprotein cholesterol, -30.0% in high density lipoprotein cholesterol and +14.5% in              triglycerides. The reduction in low density lipoprotein cholesterol apparently improved the clinical status of these     patients despite the associated drop in high density lipoprotein cholesterol. In the 19 patients who underwent coronary   arteriography before admission to the study, follow-up arteriograms showed that combined treatment stabilized the        progression of established lesions and prevented the formation of new ones. Side effects occurred mainly with monotherapy and during the early phase of combination therapy. Reactions included diarrhea, constipation, other vague abdominal      symptoms, headache and joint stiffness. In all instances, the side effects gradually subsided after the institution of   combination therapy. The combination of probucol and colestipol plus diet appears to be effective in treating most       patients with familial hypercholesterolemia.